Prenatal morphine exposure decreases analgesia but not K+ channel activation

NeuroReport

Volumn 14, Issue 2, 2003, Pages 239-242

  Chiou, Lih Chu ^a   Yeh, Geng Chang ^c   Fan, Shu Huai ^a   How, Cheng Hung ^a   Chuang, Kuang Chieh ^a   Tao, Pao Luh ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c NONE

Author keywords

Opioid receptors; Analgesia; Antinociception; Inwardly rectifying K+ channels; Morphine tolerance; Offspring toxicity; Periaqueductal gray

Indexed keywords

ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; INWARDLY RECTIFYING POTASSIUM CHANNEL; MORPHINE; MU OPIATE RECEPTOR; POTASSIUM CHANNEL; SODIUM CHLORIDE; TRITIUM;

ADAPTATION; AMYGDALOID NUCLEUS; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; BRAIN CORTEX; BRAIN ELECTROPHYSIOLOGY; BRAIN NERVE CELL; BRAIN SLICE; CHANNEL GATING; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; FEMALE; HIPPOCAMPUS; HYPERALGESIA; MESENCEPHALON; MORPHINE TOLERANCE; NONHUMAN; NUCLEUS ACCUMBENS; PERIAQUEDUCTAL GRAY MATTER; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RECEPTOR AFFINITY; RECEPTOR DENSITY; TAIL FLICK TEST; THALAMUS;

ANIMALS; FEMALE; MORPHINE; PAIN MEASUREMENT; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU;

EID: 0345269235     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200302100-00016     Document Type: Article

References (22)

1. O'Callaghan JP and Holtzman SG. J Pharmacol Exp Ther 197, 533-544 (1976).
2. Alleva E, Laviola G and Bignami G. Psychopharmacology 92, 438-440 (1987).
3. Tao PL, Yeh GC, Su CH et al. Life Sci 69, 2439-2450 (2001).
4. Rimanoczy A and Vathy I. Brain Res 690, 245-248 (1995).
5. Tempel A, Yang J and Basheer R. Brain Res Mol Brain Res 33, 227-232 (1995).
6. De Vries TJ, Van Vliet BJ, Hogenboom F et al. Eur J Pharmacol 208, 97-104 (1991).
7. Basheer R, Yang J and Tempel A. Brain Res Dev Brain Res 70, 145-148 (1992).
8. Yang SN, Yang JM, Wu JN et al. Hippocampus 10, 654-662 (2000).
9. Yaksh TL, Yeung JC and Rudy TA. Brain Res 114, 83-103 (1976).
10. Chieng B and Christie MJ. Br J Pharmacol 113, 121-128 (1994).
11. Han SH, Cho YW, Kim CJ et al. Neuroscience 90, 209-219 (1999).
12. Chiou LC and How CH. J Pharmacol Exp Ther 298, 493-500 (2001).
13. Behbehani MM, Jiang M and Chandler SD. Neuroscience 38, 373-380 (1990).
14. Chiou LC and Huang LYM. J Physiol 518, 551-559 (1999).
15. d'Amour FE and Smith DL. J Pharmacol Exp Ther 72, 74-79 (1941).
16. Chiou LC. Br J Pharmacol 128, 103-107 (1999).
17. Chiou LC. Naunyn Schmiedeberg's Arch Pharmacol 363, 583-589 (2001).
18. Chieng B and Christie MJ. J Neurosci 15, 7128-7136 (1996).
19. Tao PL, Lee CR, Law PY et al. Naunyn-Schmiedeberg's Arch Pharmacol 348, 504-508 (1993).
20. Sim LJ, Selley DA, Dworkin SI et al. J Neurosci 16, 2684-2692 (1996).
21. Ingram SL, Vaughan CW, Bagley EE et al. J Neurosci 18, 10269-10276 (1998).
22. Tortorici V, Morgan MM and Vanegas H. Pain 89, 237-244 (2001).